The Potential Applications of Gene Transfer in the Treatment of Patients with Cancer: A Concise Review

References

• Rosenberg S A, Longo D L, Lotze M T. Principles and applications of biologic therapy. Cancer-Principles and Practice of Oncology, Vol in, V T DeVita, Jr, S Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1989; 301–437
   Google Scholar
• Rosenberg S A. Immunotherapy and gene therapy of cancer. Cancer Res 1991; 51(Suppl)5074s–5079s
   PubMedGoogle Scholar
• Karp J E, Broder S. New directions in molecular medicine. Cancer Res 1994; 54: 653–665
   PubMed Web of Science ®Google Scholar
• Dorudi S, Northover J MA, Vile R G. Gene transfer therapy in cancer. Br J Surg 1993; 80: 566–572
   PubMed Web of Science ®Google Scholar
• Miller A D. Human gene therapy comes of age. Nature 1992; 356: 455–460
   Google Scholar
• Wu G Y, Wu C H. Delivery systems for gene therapy. Biotherapy 1991; 3: 87–95
   PubMedGoogle Scholar
• Guild B C, Finer M H, Housman D E, et al. Development of retrovirus vectors useful for expressing genes in cultured murine embryonal cells and hematopoietic cells in vivo. J Virol 1988; 62: 3795–3801
   PubMed Web of Science ®Google Scholar
• Zwiebel J A, Freeman S M, Kantoff P W, et al. High-level recombinant gene expression in rabbit endothelial cells transduced by retroviral vectors. Science 1989; 243: 220–222
   PubMed Web of Science ®Google Scholar
• Morin J E, Lubeck M D, Barton J E, et al. Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Proc Natl Acad Sci USA 1987; 84: 4626–4630
   PubMed Web of Science ®Google Scholar
• Doren K V, Hanahan D, Ghizman Y. Infection of eucaryotic cells by helper-independent recombinant adenoviruses: Early region 1 is not obligatory for integration of viral DNA. J Virol 1984; 50: 606–614
   PubMed Web of Science ®Google Scholar
• Mulligan R C, Howard B H, Berg P. Synthesis of rabbit beta-globin in cultured monkey kidney cells following infection with a SV40 beta-globin recombinant genome. Nature 1979; 277: 108–114
   PubMed Web of Science ®Google Scholar
• Hamer D H, Smith K D, Boyer S H, et al. SV40 recombinants carrying rabbit beta-globin coding sequences. Cell 1979; 17: 725–735
   PubMed Web of Science ®Google Scholar
• Rasmussen C D, Simmen R CM, MacDougall E A, et al. Methods for analyzing bovine papilloma virus-based calmodulin expression vectors. Methods Enzymol 1987; 139: 642–654
   PubMed Web of Science ®Google Scholar
• Paoletti E, Lipinskas B R, Samsonoff C, et al. Construction of live vaccines using genetically engineered proxviruses: Biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein B. Proc Natl Acad Sci USA 1984; 81: 193–197
   PubMed Web of Science ®Google Scholar
• Coupar B EH, Andrew M E, Boyle D B. A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes. Gene 1988; 68: 1–10
   PubMed Web of Science ®Google Scholar
• Moss B, Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol 1987; 5: 305–324
   PubMed Web of Science ®Google Scholar
• Shih M-F, Arsenakis M, Tiollais P, et al. Expression of hepatitis B virus S gene by herpes simplex virus type 1 vectors carrying alpha-and beta-regulated gene chimeras. Proc Natl Acad Sci USA 1984; 81: 5867–5870
   PubMed Web of Science ®Google Scholar
• Margolskee R F, Kavathas P, Berg P. Epstein-Barr virus shuttle vector for stable episomal replication of cDNA expression libraries in human cells. Mol Cell Biol 1988; 8: 2837–2847
   PubMed Web of Science ®Google Scholar
• Graham F L, van der E AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456–467
   PubMed Web of Science ®Google Scholar
• Wigler M, Silverstein S, Lee L.-S., et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 1977; 11: 223–232
   PubMed Web of Science ®Google Scholar
• Nicholson M O, McAllister R M. Infectivity of human adenovirus-1 DNA. Virology 1972; 48: 14–21
   PubMed Web of Science ®Google Scholar
• Harland R, Weintraub H. Translation of mRNA injected into Xenopus oocytes is specifically inhibited by antisense RNA. J Cell Biol 1985; 101: 1094–1099
   PubMed Web of Science ®Google Scholar
• Capecchi M R. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980; 22: 479–488
   PubMed Web of Science ®Google Scholar
• Potter H, Weir L, Leder P. Enhancer-dependent expression of human k immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci USA 1984; 81: 7161–7165
   PubMed Web of Science ®Google Scholar
• Fechheimer M, Boylan J F, Parker S, et al. Transfer of mammalian cells with plasmid DNA by scrape loading and sonication loading. Proc Natl Acad Sci USA 1987; 84: 8463–8467
   PubMed Web of Science ®Google Scholar
• Okada C Y, Rechsteiner M. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell 1982; 29: 33–41
   PubMed Web of Science ®Google Scholar
• Borle A B, Freudenrich C C, Snowdowne K W. A single method for incorporating aequorin into mammalian cells. Am J Physiol 1986; 251: C 323–C 326
   Google Scholar
• Nicolan C, Sene C. Liposome-mediated DNA transfer in eukaryotic cells: Dependence of the transfer efficiency upon the type of liposomes used and the host cell cycle stage. Biochim Biophys Acta 1982; 721: 185–190
   PubMed Web of Science ®Google Scholar
• San H, Yang Z.-Y, Pompili V J, et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781–788
   PubMed Web of Science ®Google Scholar
• Doxsey S J, Sambrook J, Helenius A, et al. An efficient method for introducing macromolecules into living cells. J Cell Biol 1985; 101: 19–27
   PubMed Web of Science ®Google Scholar
• Schlegel R A, Rechsteiner M C. Microinjection of thymidine kinase and bovine serum albumin into mammalian cells by fusion with red blood cells. Cell 1975; 5: 371–379
   PubMed Web of Science ®Google Scholar
• Armentano D, Yu S.-F, Kantoff P W, et al. Effect of internal viral sequences on the utility of retroviral vectors. J Virol 1987; 61: 1647–1650
   PubMed Web of Science ®Google Scholar
• Bender M A, Palmer T D, Gelinas R E, et al. Evidence that the packaging signal of Moloney leukemia virus extends into the gag region. J Virol 1987; 61: 1639–1646
   PubMed Web of Science ®Google Scholar
• Miller D O, Adam M. A., Miller A D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239–4242
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J A, Cowan K H, Wilson W, et al. Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. Hum Gene Ther 1993; 4: 331–354
   PubMed Web of Science ®Google Scholar
• Rosenberg S A, Aebersold P, Cornetta K, et al. Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infilitrating lymphocytes modified by retroviral gene transduction. N Engl J Med 1990; 323: 570–578
   PubMed Web of Science ®Google Scholar
• Rill D R, Moen R C, Buschle M, et al. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer. Blood 1992; 79: 2694–2700
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rillr D., Holladay M S. Gene marking to determine whether autologous marrow infusion restores long-term haematopoiesis in cancer patients. Lancet 1993; 342: 1134–1137
   PubMed Web of Science ®Google Scholar
• Deisseroth A B, Zu Z, Claxton D, et al. Genetic marking shows the Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Miller A R, Skotzko M J, Rhoades K, et al. Simultaneous use of two retroviral vectors in human gene marking trials: Feasibility and potential applications. Hum Gene Ther 1992; 3: 619–624
   PubMed Web of Science ®Google Scholar
• Tepper R I, Mule J J. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153–164
   PubMed Web of Science ®Google Scholar
• Douvdevani A, Huleihel M, Zoller M, et al. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int J Cancer 1992; 51: 822–830
   PubMed Web of Science ®Google Scholar
• Uchiyama A, Hoon D SB, Morisaki T, et al. Transfection of interleukin 2 gene into human melanoma cells augment cellular immune response. Cancer Res 1993; 53: 949–952
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Zier K, Daniels B, et al. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217–1224
   PubMed Web of Science ®Google Scholar
• Bubenik J, Simova J, Jandlova T. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 1990; 23: 287–292
   PubMed Web of Science ®Google Scholar
• Russell S J, Eccles S A, Hemming C L, et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int J Cancer 1991; 47: 244–251
   PubMed Web of Science ®Google Scholar
• Ley V, Langlade-Demoyen P, Kourilsky P, et al. Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur J Immunol 1991; 21: 851–854
   PubMed Web of Science ®Google Scholar
• Fearon E R, Pardoll D M, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397–403
   PubMed Web of Science ®Google Scholar
• Karp S E, Farber A, Salo J C, et al. Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma: Tumor inhibition by IL-2 but not by tumor necrosis factor. J Immunol 1993; 150: 896–908
   PubMed Web of Science ®Google Scholar
• Yu J S, Wei M X, Chiocca E A, et al. Treatment of glioma by engineered interleukin 4-secreting cells. Cancer Res 1993; 53: 3125–3128
   PubMed Web of Science ®Google Scholar
• Li W, Diamantstein T, Blankenstein T. Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to antitumor function of interleukin 4. Mol Immunol 1990; 27: 1331–1337
   PubMed Web of Science ®Google Scholar
• Golumbek P T, Lasenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713–716
   PubMed Web of Science ®Google Scholar
• Tepper R I, Pattengale P K, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503–512
   PubMed Web of Science ®Google Scholar
• Sun W H, Kreisle R A, Phillips A W, et al. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res 1992; 52: 5412–5415
   Google Scholar
• Mullen C A, Coale M, Levy A T, et al. Fibrosarcoma cells transduced with the IL-6 gene exhibit reduced tumorigenicity, increased immunogenicity and decreased metastatic potential. Cancer Res 1992; 52: 6020–6024
   PubMed Web of Science ®Google Scholar
• Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 1992; 52: 3679–3686
   PubMed Web of Science ®Google Scholar
• Hock H, Dorsch M, Diamantstein T, et al. Interleukin 7 induces CD4+ T cell-dependent tumor rejection. J Exp Med 1991; 174: 1291–1298
   PubMed Web of Science ®Google Scholar
• Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Pro Natl Acad Sci USA 1992; 89: 3850–3854
   PubMed Web of Science ®Google Scholar
• Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci USA 1993; 90: 2774–2778
   PubMed Web of Science ®Google Scholar
• Jicha D L, Mule J J, Rosenberg S A. Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 1991; 174: 1511–1515
   PubMed Web of Science ®Google Scholar
• McBride W H, Thacker J D, Comora S, et al. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity. Cancer Res 1992; 52: 3931–3937
   PubMed Web of Science ®Google Scholar
• Tahara H, Zeh H. J., III, Storkus W J, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182–189
   PubMed Web of Science ®Google Scholar
• Colombo M P, Ferrari G, Stoppacciaro A, et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889–897
   PubMed Web of Science ®Google Scholar
• Stoppacciaro A, Melani C, Parenza M, et al. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon-gamma. J Exp Med 1993; 178: 151–161
   PubMed Web of Science ®Google Scholar
• Jaffee E M, Dranoff G, Cohen L K, et al. High efficiency gene transfer into primary human tumor explants without cell selection. Cancer Res 1993; 53: 2221–2226
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543
   PubMed Web of Science ®Google Scholar
• Teng M N, Park B H, Koeppen H KW, et al. Long-term inhibition of tumor growth by tumor necrosis factor on the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991; 88: 3535–3539
   PubMed Web of Science ®Google Scholar
• Asher A L, Mule J J, Kasid A, et al. Murine tumor cells transduced with the gene for tumor necrosis factor-alpha: Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol 1991; 146: 3227–3234
   PubMed Web of Science ®Google Scholar
• Blankenslein T, Quin Z, Uberla K, et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 1991; 173: 1047–1052
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuoblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456–9460
   PubMed Web of Science ®Google Scholar
• Gansbacher B, Bannerji R, Brian D, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and lasting antitumor immunity. Cancer Res 1990; 50: 7820–7825
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Proietti E, Santodonato L, et al. Alpha1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: Antitumor therapy by means of interferon-producing cells. Cancer Res 1993; 53: 1107–1112
   PubMed Web of Science ®Google Scholar
• Torre-Amione G, Beauchamp D, Koeppen H, et al. A highly immunogenic tumor transfected with a murine transforming growth factor type beta1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 1990; 87: 1486–1490
   PubMed Web of Science ®Google Scholar
• Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993; 177: 1127–1134
   PubMed Web of Science ®Google Scholar
• Tan Y, Wang W, Wang B, et al. Potential clinical efficacy and lack of toxicity of IL-2 gene therapy of advanced lung cancer patients. Proc Am Soc Clin Oncol 1994; 13: 328, (abstract)
   Google Scholar
• Osanto S, Brouwenstijn N, Vaessen N, et al. Gene therapy of metastatic melanoma patients with IL-2 transfected melanoma cells. Proc Am Soc Clin Oncol 1994; 13: 293, (abstract)
   Google Scholar
• Townsend S E, Allison J P. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368–370
   PubMed Web of Science ®Google Scholar
• Harding F A, Allison J P. CD28-B7 interaction allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993; 177: 1791–1796
   PubMed Web of Science ®Google Scholar
• Plautz G E, Yang Z.-Y., Wu B-Y, et al. Immunotherapy of malignancy by in vivo transfer into tumors. Proc Natl Acad Sci USA 1993; 90: 4645–4649
   PubMed Web of Science ®Google Scholar
• Nabel G J, Chang A E, Nabel E G, et al. Immunotherapy for cancer by direct gene transfer into tumors. Hum Gene Ther 1994; 5: 57–77
   PubMed Web of Science ®Google Scholar
• Helene C. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur J Cancer 1991; 27: 1466–1471
   PubMed Web of Science ®Google Scholar
• Cohen J S. Selective anti-gene therapy for cancer: Principles and prospects. Tohoku J Exp Med 1992; 168: 351–359
   PubMed Web of Science ®Google Scholar
• Hanvey J C, Peffer N J, Bisi J E, et al. Antisense and antigene properties of peptide nucleic acids. Science 1992; 258: 1481–1485
   PubMed Web of Science ®Google Scholar
• Wickstrom E L, Bacon T A, Gonzalez A, et al. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci USA 1988; 85: 1028–1032
   PubMed Web of Science ®Google Scholar
• Calabretta B, Sims R B, Valtieri M, et al. Normal and leukemic hematopoietic cells manifest differential sensitivity in inhibitory effects of c-myb antisense oligonucleotides: An in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991; 88: 2351–2355
   PubMed Web of Science ®Google Scholar
• Van Waardenburg R CAM, Prins J, Meijer C, et al. Inhibition of c-myc oncogene expression with a c-myc antisense oligonucleotide and its effects on proliferation and drug sensitive and resistant human small cell lung cancer cells. Proc Am Assoc Cancer Res 1994; 35: 615, (abstract)
   Google Scholar
• Joshi S S, Verbik D J, Tomes D J, et al. Growth inhibition of human Burkitt's lymphoma cells by c-myc-antisense oligodeoxynucleotides in vitro. Proc Am Assoc Cancer Res 1994; 35: 617, (abstract)
   Google Scholar
• Bergan R C, Kyle E L, Neckers L M. Electroporation of lymphoma cells with c-myc antisense oligonucleotides: A model for bone marrow purging. Proc Am Assoc Cancer Res 1994; 35: 308, (abstract)
   Google Scholar
• Ratajczak M Z, Kant J A, Luger S M, et al. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci US A 1992; 89: 11823–11827
   PubMed Web of Science ®Google Scholar
• Ratajczak M Z, Hijiya N, Catani L, et al. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 1992; 79: 1956–1961
   PubMed Web of Science ®Google Scholar
• Szczylik C, Skorski T, Nicholaides N C, et al. Selective inhibition of leukemia cell proliferation BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253: 562–565
   PubMed Web of Science ®Google Scholar
• Martial P, Lewalle P, Taj A S, et al. Retrovirally transduced anti-sense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-contaming cell lines. Blood 1993; 81: 502–509
   PubMed Web of Science ®Google Scholar
• Tari A, Tucker S, Deisseroth A, et al. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotodes in chronic myelogenous leukemia. Proc Am Assoc Cancer Res 1994; 35: 308, (abstract)
   Google Scholar
• Okabe M, Kunieda Y, Miyagishmia T, et al. BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to BCR/ABL mRNA. and herbimycin A, an antagonist of protein tyrosine kinase: Inhibitory effects on in vitro growth of Ph -positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells. Leukemia Lymphoma 1993; 10: 307–316
   PubMed Web of Science ®Google Scholar
• Trojan J, Johnson T R, Rubin S D, et al. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94–97
   PubMedGoogle Scholar
• Hirschfeld S, Helman L J. Proliferation of leiomyosarcoma cell lines is inhibited by antisense oligonucleotides directed against the insulin growth factor type I receptor. Proc Am Assoc Cancer Res 1994; 35: 258, (abstract)
   Google Scholar
• Daaka Y, Wickstrom E. Target dependence of antisense oligodeoxynucleotide inhibition of c-Ha-ras p21 expression and focus formation in T24-transformed NIH3T3 cells. Oncogene Res 1990; 5: 267–275
   PubMedGoogle Scholar
• Brown D, Yu Z, Miller P, et al. Modulation of ras expression by anti-sense, nonionic deoxyoligonucleotide analogs. Oncogene Res 1989; 4: 243–252
   PubMedGoogle Scholar
• Saison-Behmoaras T, Tocque B, et al. Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation. EMBO J 1991; 10: 1111–1118
   PubMed Web of Science ®Google Scholar
• Zhang Y, Mukhopadhyay T, Donehower L A, et al. Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Hum Gene Trier 1993; 4: 451–460
   PubMed Web of Science ®Google Scholar
• Birchenall-Roberts M C, Ferrer C, Ferris D, et al. Inhibition of murine monocyte proliferation by a colony-stimulating factor-1 antisense oligodeoxynucleotide: Evidence for autocrine regulation. J Immunol 1990; 145: 3290–3296
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu J.-Q., Han K-K, et al. The role of the c-fms oncogene in the regulation of HL-60 cell differentiation. Oncogene 1990; 5: 873–877
   PubMed Web of Science ®Google Scholar
• Schwab G, Siegall C B, Aarden L A, et al. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 587–593
   PubMed Web of Science ®Google Scholar
• Blay J-Y, Bolon I, Alberti L, et al. Growth inhibition of renal carcinoma cell lines by interleukin-6 antisense oligonucleotides: An internal autocrine loop. Proc Am Assoc Cancer Res 1994; 35: 615, (abstract)
   Google Scholar
• Becker D, Meier C, Herlyn M. Proliberation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 1989; 8: 3685–3691
   PubMed Web of Science ®Google Scholar
• Wismeth C, Jager A, Brysch W, et al. Specific PTO-antisense oligonucleotide therapy in malignant glidmas—An vitro study. Proc Am Assoc Cancer Res 1994; 35: 617, (abstract)
   Google Scholar
• Dunn M, Fonagy A, Swiderski C. P120 antisense-mediated inhibition of breast cancer cell growth. Proc Am Assoc Cancer Res 1994; 35: 530, (abstract)
   Google Scholar
• Busch R K, Valdez B C, Henning D, et al. Apoptotic cell death in human tumor cells following treatment with P120 antisense oligonucleotide ISIS-3466. Proc Am Assoc Cancer Res 1994; 35: 308, (abstract)
   Google Scholar
• Dooley N P, Baltuch G H, Yong V W. Phosphorothioate antisense oligonucleotides to protein kinase C (PKC) alpha inhibit proliferation in rat C6 glioma. Proc Am Assoc Cancer Res 1994; 35: 566, (abstract)
   Google Scholar
• Staley C A, Parikh N U, Gallick G E. Inhibition of the growth of HT-29 human colon adenocarcinoma cell lines by an antisense oligonucleotide to pp60c-src. Proc Am Assoc Cancer Res 1994; 35: 530, (abstract)
   Google Scholar
• Cheng J Q, Ruggeri B, Altomare D A, et al. Amplification of AKT2 in human pancreatic cancer cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Am Assoc Cancer Res 1994; 35: 530, (abstract)
   Google Scholar
• Fujiwara T, Grimm E A, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994; 54: 2287–2291
   PubMed Web of Science ®Google Scholar
• Hirota Y, Akahane K, Horiuchi T. p53 antisense oligonucleotides inhibit growth of human tumor cell lines. Proc Am Assoc Cancer Res 1994; 35: 609, (abstract)
   Google Scholar
• Janicek M, Nguyen H, Sevin B U, et al. Combination gene therapy targeting MYC and P53 in endometrial cancer cell lines. Proc Am Soc Clin Oncol 1994; 13: 122, (abstract)
   Google Scholar
• Li M, Kramer R. Retroviral gene transfer of anti-ras ribozyme into tumor cells with activated ras oncogene. Proc Am Assoc Cancer Res 1994; 35: 373, (abstract)
   Google Scholar
• Ohta Y, Kijima H, Kashfian B I, et al. Supression of malignant melanoma phenotype by anti-oncogene ribozymes. Proc Am Assoc Cancer Res 1994; 35: 308, (abstract)
   Google Scholar
• Calabretta B, Skorski T, Szczylik C, et al. Prospects of gene-directed therapy with antisense oligodeoxynucleotides. Cancer Treat Rev 1993; 19: 169–179
   PubMed Web of Science ®Google Scholar
• Bishop M R, Bayever E, Iversen P L, et al. Phase I trial of systemic administration of OL (1) p53 oligonucleotide in refractory acute myelogenous leukemia and advanced myetodysplastic syndrome. Blood 1993; 82(Suppl l)443a, (abstract)
   Google Scholar
• Bishop M R, Tarantolo S R, Bayever E, et al. Autologous bone marrow (ABM) treated ex-vivo with oligonucleotide OL (1) p53 for transplantation in acute myelogenous leukemia (AML). Blood 1994; 13(Suppl 1)312, (abstract)
   Google Scholar
• Moolten F L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–5281
   PubMed Web of Science ®Google Scholar
• Ram Z, Culver K W, Walbridge S, et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res 1993; 53: 83–88
   PubMed Web of Science ®Google Scholar
• Ezzeddine Z D, Martuza R L, Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol 1991; 3: 608–614
   PubMedGoogle Scholar
• Moolten F L, Wells J M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990; 82: 297–300
   PubMed Web of Science ®Google Scholar
• Borrelli E, Heyman R, Hsi M, et al. Targeting of an inducible toxic phenotype in animal cells. Proc Natl Acad Sci USA 1988; 85: 7572–7576
   PubMed Web of Science ®Google Scholar
• Bi W L, Parysek L M, Warnick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993; 4: 725–731
   PubMed Web of Science ®Google Scholar
• Culver K W, Ram Z, Walbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552
   PubMed Web of Science ®Google Scholar
• Plautz G, Nabel E G, Nabel G J. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 1991; 3: 709–715
   PubMedGoogle Scholar
• Takamiya Y, Short M P, Ezzeddine Z D, et al. Gene therapy on malignant brain tumors: A rat glioma line bearing the herpes simplex virus type 1-thymidine kinase gene and wild type retro-virus kills other tumor cells. J Neurosci Res 1992; 33: 493–503
   PubMed Web of Science ®Google Scholar
• Sugaya S, Fujita K, Tanaka K. Tumor cell specific expression of herpes simplex thymidine kinase gene promoted by MYC binding sequence. Proc Am Assoc Cancer Res 1994; 35: 376, (abstract)
   Google Scholar
• Mouawad R, Soubrane C I, Salzmann J L, et al. Regression of experimental murine melanoma after in situ transduction of a suicide gene. Proc Am Assoc Cancer Res 1994; 35: 210, (abstract)
   Google Scholar
• Loeb L A, Munir K, Black M E. Creation of herpes thymidine kinase mutants for gene therapy. Proc Am Assoc Cancer Res 1994; 35: 375, (abstract)
   Google Scholar
• Chen S-H, Shine H D, Goodman J C, et al. Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Am Assoc Cancer Res 1994; 35: 420, (abstract)
   Google Scholar
• Shewach D S, Zerbe L K, Breakefield X O, et al. Approaches to enhance gene transfer therapy with herpes simplex virus thymidine kinase in cultured rat glioma cells. Proc Am Assoc Cancer Res 1994; 35: 374, (abstract)
   Google Scholar
• Link C J, Beecham E, McCann L, et al. In vivo combination gene therapy with the herpes simplex thymidine kinase (HS-tk) and interleukin-2 (IL-2) genes for the treatment of ovarian cancer. Proc Am Soc Clin Oncol 1994; 13: 256, (abstract)
   Google Scholar
• Mullen C A, Kilstrup M, Blaese R M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc Natl Acad Sci USA 1992; 89: 33–37
   PubMed Web of Science ®Google Scholar
• Fairchild C R, Cowan K H. Multidrug resistance: A pleiotropic response to cytotoxic drugs. Int J Radial Oncol Bio Phys 1991; 20: 361–367
   PubMed Web of Science ®Google Scholar
• Moscow J A, Cowan K H. Multidrug resistance. J Natl Cancer Inst 1988; 80: 14–20
   PubMed Web of Science ®Google Scholar
• Biedler J L. Drug resistance: Genotype versus phenotype—Thirty-Second G.H.A. Clowes Memorial Award Lecture. Cancer Res 1994; 54: 666–678
   PubMed Web of Science ®Google Scholar
• Lincke C R, van der bliek A M, Schuurhuis G J, et al. Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1. Cancer Res 1990; 50: 1779–1785
   PubMed Web of Science ®Google Scholar
• Nooter K, Boesen J JB, Van Beusechem V W, et al. Retroviral mediated transfer of the human mdr1 gene into bone marrow cells. Proc Am Assoc Cancer Res 1994; 35: 373, (abstract)
   Google Scholar
• Shaughnessy E, Wong K K, Podsakoff G, et al. Adeno-associated virus vectors for MDR-1 gene therapy. Proc Am Assoc Cancer Res 1994; 35: 373, (abstract)
   Google Scholar
• Kane S E, Metz M Z, Matsumoto L, et al. Novel retroviral vectors for transducing two therapeutic genes for gene therapy of human hematopoietic cells. Proc Am Assoc Cancer Res 1994; 35: 373, (abstract)
   Google Scholar
• Aksentijevich I, Germann U A, Licht T, et al. Variable MDR1 transduction efficiency in different mammalian cells. Proc Am Assoc Cancer Res 1994; 35: 375, (abstract)
   Google Scholar
• Hanania E G, Fu S.-Q., Hegewisch-Becker S, et al. Gene-therapy animal model to evaluate the long term effect and the efficiency of using the multiple drug resistance gene retroviral vectors in conferring the chemoresistance phenotype upon early progenitor cells. Proc Am Assoc Cancer Res 1994; 35: 210, (abstract)
   Google Scholar
• Sorrentino B P, Brandt S J, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• DelaFlor-Weiss E, Richardson C, Ward M, et al. Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 1992; 80: 3106–3111
   PubMed Web of Science ®Google Scholar
• Mazzanti R, Fantappie' O, Fabrizio P, et al. Confering multiple drug resistance by mar1 gene transfection increases susceptibility to irradiation and lipid peroxidation. Proc Am Assoc Cancer Res 1994; 35: 10, (abstract)
   Google Scholar
• Greenbaum M, Letourneau S, Assar H, et al. Retrovirus-mediated gene transfer of glutathione S-transferase confers resistance to alkylating agents. Proc Am Assoc Cancer Res 1994; 35: 373, (abstract)
   Google Scholar
• Sugimoto Y, Aksentijevich I, Aran J M, et al. Generation of MDR1 retroviral vectors which coexpress a second gene under the control of a single promoter. Proc Am Assoc Cancer Res 1994; 35: 375, (abstract)
   Google Scholar
• Kondo S, Yin D, Morimura T, et al. Transfection with a bcl-2 expression vector protests transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res 1994; 54: 2928–2933
   PubMed Web of Science ®Google Scholar